Lab-Grown Fat Cells Model Rare Lipodystrophy
Researchers built stem-cell-derived fat cells carrying a common LMNA variant to study familial partial lipodystrophy type 2.
Updated on Nov. 2, 2026 in Life Sciences
Scientists engineered an isogenic induced pluripotent stem cell model carrying the LMNA p.R482W variant, the most common cause of familial partial lipodystrophy type 2. The model adipocytes showed impaired glucose uptake and reduced metabolic activity compared with isogenic controls.
Why it matters
Familial partial lipodystrophy type 2 causes selective loss of subcutaneous fat, severe insulin resistance, and dyslipidemia, and a lab model that reproduces these defects gives researchers a way to study disease mechanisms directly. The model's gene expression patterns also matched single-nucleus data from adipose tissue biopsies of affected individuals.
In vitro Seahorse measurements showed oxygen consumption of 126.5 versus 261.5 pmol/min and acidification of 27.6 versus 46.7 mpH/min in mutant versus control cells, with 59.5% of 37 shared pathways concordant with patient adipose tissue. Whether these cell-level metabolic deficits fully mirror disease in the body is not addressed in the study summary.
The details
Using CRISPR/Cas9, the team introduced the heterozygous LMNA c.1444C>T (p.R482W) variant into a healthy donor-derived iPSC line, then differentiated the cells into adipocytes with a transgene-free mesenchymal progenitor protocol. Mutant adipocytes showed downregulated adipogenic, lipid-handling, and extracellular matrix genes and impaired glucose uptake under basal and insulin-stimulated conditions.
The Big Picture
Stem-cell models of LMNA-related disease extend a growing research approach in which patient-derived iPSCs are used to study tissue-specific laminopathies. This work applies that method to adipocytes, a cell type central to the metabolic complications of familial partial lipodystrophy type 2.
Stem-cell models like this one could eventually help researchers test drug candidates for lipodystrophy-related insulin resistance without relying solely on patient tissue samples. The study does not describe any treatment now available to patients.
The takeaway
Patient-derived stem-cell models can reveal how a single gene variant disrupts fat cell function, offering a path toward better disease research. Readers interested in metabolic genetics can follow ongoing laminopathy studies as this field develops.
Further reading
Explore more Life Sciences research on how genetic variants drive metabolic disease.
Source note: This article includes information reported by Biorxiv.
